Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
TRK fusions are highly actionable driver alterations. A. Drilon gives an overview of their frequency in different cancer types, and explains how to screen for these alterations with next generation sequencing, immunohistochemistry or FISH.
He details the targeted therapies which have shown very high and durable response rates, as well as the mechanisms of resistance and how to tackle it.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
